Skip to main content

Table 3 Logistic regression model of the probability of treatment discontinuation

From: Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis

 

Estimated OR

95% CI

P-value

Unadjusted model

 CsA (ref OTX-101)

1.41

(1.24 to 1.61)

< 0.001

 LFT (ref OTX-101)

1.01

(0.89 to 1.14)

0.917

Adjusted model

 CsA (ref OTX-101)

1.35

(1.16 to 1.57)

< 0.001

  Age > 64 (ref ≤ 64), years

1.27

(1.07 to 1.51)

0.007

  Quan-CCI

0.98

(0.94 to 1.02)

0.343

  Eye-related comorbidities (ref no)

0.90

(0.76 to 1.08)

0.262

  Insurance (ref commercial)

   Employer

0.87

(0.66 to 1.15)

0.336

   Medicaid

0.62

(0.47 to 0.82)

0.001

   Medicare

0.94

(0.78 to 1.12)

0.478

 LFT (ref OTX-101)

0.97

(0.84 to 1.12)

0.718

  Age > 64 (ref ≤ 64), years

1.15

(0.97 to 1.37)

0.118

  Quan-CCI

0.99

(0.95 to 1.04)

0.788

  Eye-related comorbidities (ref no)

0.85

(0.72 to 1.01)

0.067

  Insurance (ref commercial)

   Employer

0.88

(0.69 to 1.10)

0.259

   Medicaid

0.79

(0.62 to 1.01)

0.060

   Medicare

0.79

(0.66 to 0.96)

0.015

  1. CI Confidence interval, CsA Cyclosporine ophthalmic emulsion 0.05%, LFT Lifitegrast ophthalmic solution 5%, OR Odds ratio, OTX-101 Cyclosporine ophthalmic solution 0.09%, Quan-CCI Quan-Charlson Comorbidity Index, ref reference
  2. Indicates statistical significance as based on P-value < 0.05